# Zoetis Inc.: overview

ZTS · NYSE · CIK 1555280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/zts.md) · [Financials](/companies/zts/financials.md) · [Filings](/companies/zts/filings.md) · [Insiders](/companies/zts/insiders.md)

Latest reported revenue: [$2.47bn](/filings/0001555280-26-000040.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001555280-26-000040).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,388](/filings/0001555280-25-000274.md) | [2,317 d](/filings/0001555280-26-000011.md) | [2,198](/filings/0001555280-26-000024.md) | [2,474](/filings/0001555280-26-000040.md) | [2,400](/filings/0001555280-25-000274.md) | [2,387 d](/filings/0001555280-26-000011.md) | [2,262](/filings/0001555280-26-000024.md) | [2,468](/filings/0001555280-26-000040.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [28.6%](/filings/0001555280-25-000274.md) | [25.1% d](/filings/0001555280-26-000011.md) | [27.4%](/filings/0001555280-26-000024.md) | [29.3%](/filings/0001555280-26-000040.md) | [30.0%](/filings/0001555280-25-000274.md) | [25.3% d](/filings/0001555280-26-000011.md) | [26.6%](/filings/0001555280-26-000024.md) | [28.0%](/filings/0001555280-26-000040.md) |
| Diluted EPS | $ per share | [1.50](/filings/0001555280-25-000274.md) | not reported | [1.34](/filings/0001555280-26-000024.md) | [1.63](/filings/0001555280-26-000040.md) | [1.63](/filings/0001555280-25-000274.md) | not reported | [1.42](/filings/0001555280-26-000024.md) | [1.65](/filings/0001555280-26-000040.md) |
| Free cash flow | $m | [784 d](/filings/0001555280-25-000274.md) | [689 d](/filings/0001555280-26-000011.md) | [337](/filings/0001555280-26-000024.md) | [459 d](/filings/0001555280-26-000040.md) | [755 d](/filings/0001555280-25-000274.md) | [732 d](/filings/0001555280-26-000011.md) | [291](/filings/0001555280-26-000024.md) | [538 d](/filings/0001555280-26-000040.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [7,776](/filings/0001555280-24-000143.md) | [8,080](/filings/0001555280-25-000102.md) | [8,544](/filings/0001555280-26-000011.md) | [9,256](/filings/0001555280-26-000011.md) | [9,467](/filings/0001555280-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [26.2%](/filings/0001555280-24-000143.md) | [26.2%](/filings/0001555280-25-000102.md) | [27.4%](/filings/0001555280-26-000011.md) | [26.9%](/filings/0001555280-26-000011.md) | [28.2%](/filings/0001555280-26-000011.md) |
| Diluted EPS | $ per share | [4.27](/filings/0001555280-24-000143.md) | [4.49](/filings/0001555280-25-000102.md) | [5.07](/filings/0001555280-26-000011.md) | [5.47](/filings/0001555280-26-000011.md) | [6.02](/filings/0001555280-26-000011.md) |
| Free cash flow | $m | [1,736](/filings/0001555280-24-000143.md) | [1,326](/filings/0001555280-25-000102.md) | [1,621](/filings/0001555280-26-000011.md) | [2,298](/filings/0001555280-26-000011.md) | [2,283](/filings/0001555280-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/zts/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.83bn | 39,430,181 |  | Added +3,845,869 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.87bn | 26,027,984 |  | Reduced −44,862 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.71bn | 23,860,445 |  | Reduced −106,955 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.41bn | 19,667,723 |  | Added +343,322 |
| [STATE FARM MUTUAL AUTOMOBILE INSURANCE CO](/funds/315032.md) | 2026-06-30 | $1.14bn | 15,892,903 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $951.8m | 13,289,622 |  | Added +1,940,374 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $677.2m | 9,423,895 |  | Reduced −726,201 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $638.0m | 8,878,849 |  | Reduced −5,266,886 |
| [NORDEA INVESTMENT MANAGEMENT AB](/funds/1218210.md) | 2026-06-30 | $471.7m | 6,592,578 |  | Added +727,467 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $437.6m | 3,701,747 |  | Not compared |

## Recent filings

[All 2,066 filings](/companies/zts/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 11:32 ET | [8-K](/filings/0001555280-26-000044.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001555280-26-000044 |
| 2026-10-08 | 20:16 ET | [8-K](/filings/0001555280-26-000042.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001555280-26-000042 |
| 2026-08-06 | 20:17 ET | [8-K](/filings/0001193125-26-338080.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-338080 |
| 2026-08-06 | 18:32 ET | [10-Q](/filings/0001555280-26-000040.md) | Quarterly report, period 2026-06-30 | 0001555280-26-000040 |
| 2026-08-06 | 11:06 ET | [8-K](/filings/0001555280-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001555280-26-000038 |
| 2026-05-22 | 23:35 ET | [8-K](/filings/0001555280-26-000029.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001555280-26-000029 |
| 2026-05-20 | 20:23 ET | [8-K](/filings/0001555280-26-000026.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001555280-26-000026 |
| 2026-05-07 | 20:26 ET | [10-Q](/filings/0001555280-26-000024.md) | Quarterly report, period 2026-03-31 | 0001555280-26-000024 |
| 2026-05-07 | 11:05 ET | [8-K](/filings/0001555280-26-000021.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001555280-26-000021 |
| 2026-04-08 | 13:01 ET | [DEF 14A](/filings/0001555280-26-000015.md) | Proxy statement, period 2025-12-31 | 0001555280-26-000015 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001555280-26-000011.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/eb46f6ee-8406-4494-a0cc-8cee418b0cb1)

## About the filer

- CIK: 1555280
- Tickers: ZTS
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.